comparemela.com

Latest Breaking News On - Cart therapy - Page 1 : comparemela.com

Optimizing BTKi Treatment Strategies

The panelists provide perspectives on critical aspects of the CLL and SLL treatment landscape.

Deborah stephensJennifer woyachRyan haumschildTara graffBryan jacobsPeer exchangeCart therapyJcdk4 6 inhibitorAnti cd38Social determinants of healthFinancial burdenFinancial toxicityEconomic burden

Key Considerations for Treating Patients Diagnosed With CLL and SLL

Medical experts provide their final thoughts regarding key treatment considerations for CLL and SLL.

Jennifer woyachTara graffRyan haumschildDeborah stephensBryan jacobsPeer exchangeBtk inhibitorsCardiac eventsToxicity profileCart therapyJcdk4 6 inhibitorAnti cd38Social determinants of healthFinancial burdenFinancial toxicityEconomic burden

Multiple Myeloma Challenges and Treatment Evolution

Gabriel Hinojosa, PharmD, BCOP, explores unmet needs and social determinants in multiple myeloma care, envisioning treatment advancements amid evolving complexities and patient disparities.

Gabriel hinojosaMultiple myelomaAutologous transplantEligibility factorsTreatment shiftsStem cell transplantationMyeloma therapyGriffin trialPerseus trialMultiple myeloma treatmentsTreatment optionsAdverse eventsDrug sequencingCellular therapiesBi specifict cell engagersCart therapy

NEXICART-1: Safety and Efficacy of NXC-201 in AL Amyloidosis

Faculty offer insights on the NEXICART-1 phase 1 clinical trial investigating the safety and efficacy of NXC-201 in patients with AL amyloidosis and discuss potential clinical implications on the study’s findings.

United statesVaishali sanchorawalaHeather landauJeffrey zonderPeer exchangeAmerican society of hematologyAmerican societyLight chain amyloidosisAl amyloidosisAffirm alNexicart 1Amyloid depositsCd 38 directed monoclonal antibodiesCardiac involvementMayo cardiac stagingStem cell transplant

Looking Ahead: Future Perspectives on AL Amyloidosis

Heather Landau, MD, invites panelists to provide their insights on the future outlook for the treatment of AL amyloidosis.

Vaishali sanchorawalaJeffrey zonderHeather landauPeer exchangeLight chain amyloidosisAl amyloidosisAffirm alNexicart 1Amyloid depositsCd 38 directed monoclonal antibodiesCardiac involvementMayo cardiac stagingStem cell transplantDuration of therapyUnmet needsManaging al amyloidosis

vimarsana © 2020. All Rights Reserved.